Page 13 - Read Online

Paraskevas. Neuroimmunol Neuroinflammation 2020;7:183-93 I http://dx.doi.org/10.20517/2347-8659.2019.008 Page 191

46. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, et al. Longitudinal change in CSF biomarkers in autosomal-dominant
Alzheimer’s disease. Sci Transl Med 2014;6:226ra30.
47. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully
changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.
48. Park JE, Choi KY, Kim BC, Choi SM, Song MK, et al. Cerebrospinal fluid biomarkers for the diagnosis of prodromal Alzheimer’s disease
in amnestic mild cognitive impairment. Dement Geriatr Cogn Dis Extra 2019;9:100-13.
49. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer’s
disease. PLoS One 2009;4:e6294.
50. Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, et al. Recommendations for CSF AD biomarkers in the diagnostic
evaluation of dementia. Alzheimers Dement 2017;13:274-84.
51. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. Association between CSF biomarkers and incipient Alzheimer’s
disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34.
52. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, et al. Diagnostic performance of a CSF-biomarker
panel in autopsy-confirmed dementia. Neurobiol Aging 2008;29:1143-59.
53. Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed
Alzheimer’s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis 2015;44:525-39.
54. Kapaki E, Liappas I, Paraskevas GP, Theotoka I, Rabavilas A. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio
for the discrimination of alcohol-related cognitive disorders from Alzheimer’s disease in the early stages. Int J Geriatr Psychiatry
2005;20:722-9.
55. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, et al. Added diagnostic value of CSF biomarkers in differential
dementia diagnosis. Neurobiol Aging 2010;31:1867-76.
56. Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, et al. Diagnostic value of CSF biomarker profile in frontotemporal
lobar degeneration. Alzheimer Dis Assoc Disord 2008;22:47-53.
57. Wallin A, Kapaki E, Boban M, Engelborghs S, Hermann DM, et al. Biochemical markers in vascular cognitive impairment associated
with subcortical small vessel disease - A consensus report. BMC Neurol 2017;17:102.
58. Paraskevas GP, Bougea A, Constantinides VC, Bourbouli M, Petropoulou O, et al. In vivo prevalence of Alzheimer biomarkers in
dementia with Lewy bodies. Dement Geriatr Cogn Disord 2019;47:289-96.
59. Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in
idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer’s disease. Eur J Neurol 2007;14:168-73.
60. Ossenkoppele R, Mattsson N, Teunissen CE, Barkhof F, Pijnenburg Y, et al. Cerebrospinal fluid biomarkers and cerebral atrophy in
distinct clinical variants of probable Alzheimer’s disease. Neurobiol Aging 2015;36:2340-47.
61. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working
Group. Consensus report of the working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. Neurobiol Aging
1998;19:109-16.
62. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic
markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-9.
63. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, et al. Recommendations for the diagnosis and management of Alzheimer’s
disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26.
64. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s
disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement 2011;7:270-9.
65. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. Toward defining the preclinical stages of Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s
disease. Alzheimers Dement 2011;7:280-92.
66. Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative
dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of
Biological Psychiatry. World J Biol Psychiatry 2018;19:244-328.
67. Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis 2018;62:1125-40.
68. Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol
2018;136:821-53.
69. Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, et al. Qualification opinion of novel methodologies in the predementia stage of
Alzheimer’s disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden-regulatory considerations by European
Medicines Agency focusing in improving benefit/risk in regulatory trials. Eur Neuropsychopharmacol 2011;21:781-8.
70. Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, et al. The road ahead to cure Alzheimer’s disease: development of biological
markers and Neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis 2014;1:181-202.
71. Jack CR Jr. PART and SNAP. Acta Neuropathol 2014;128:773-6.
72. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid b 42/40 CSF concentration ratio in the diagnostics of Alzheimer’s
disease: validation of two novel assays. J Alzheimers Dis 2015;43:183-91.
73. Jack CR Jr, Knopman DS, Chételat G, Dickson D, Fagan AM, et al. Suspected non-Alzheimer disease pathophysiology–concept and
controversy. Nat Rev Neurol 2016;12:117-24.